Harry W. Lampiris, MD

Harry W. Lampiris, MD

University of California San Francisco

Professor of Clinical Medicine
University of California San Francisco
Infectious Diseases Section, Department of Medicine
San Francisco Veteran Affairs Medical Center
San Francisco, California

Committees and Organizations

  • Executive Advisory Board, UCSF Community Consortium for HIV/Research/CPCRA
  • Member, UCSF Human Research Protection Program Policy Working Group, Committee on Human Research, UCSF
  • Elected Member, UCSF Academy of Medical Education
  • Chair, Clinical Research Subcommittee, Research and Development Committee, SFVAMC
  • Associate Program Director, Infectious Disease Fellowship Program, UCSF
  • Selection Committee Member, UCSF Categorical Medical Residency
  • Member, Pharmacy and Therapeutics Committee, SFVAMC
  • Chairman, Antibiotic Subcommittee, Pharmacy and Therapeutics Committee, SFVAMC

Honors and Awards

  • Recipient, George S. Sarlo Award for Teaching Excellence, UCSF AIDS Research Institute (2009)
  • Elected Member, Haile T. Debas Academy of Medical Educators, UCSF School of Medicine (2005)
  • Best Doctors in Bay Area, Infectious Disease, San Francisco Magazine (2005)
  • Excellence in Outpatient Teaching Award, SFVAMC Prime Program (1997)


  • Brown University, BS, Biochemistry, BA, Comparative Literature
  • University of California San Francisco, College of Medicine, MD (1985)
  • Northwestern University, McGaw Medical Center, Internal Medicine Internship and Residency (1985-1988)
  • University of California Hospitals San Francisco, Fellowship in Infectious Diseases (1989-1991)

Selected Publications

  1. H Hatano, H Lampiris, S Fransen, S Gupta, W Huang, R Hoh, JN Martin, J Lalezari, D Bangsberg, C Petropoulos, SG Deeks. Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy. JAIDS. 2010;54:380-393.
  2. AR Zolopa, DS Berger, H Lampiris, L Zhong, SL Chuck, J Enejosa BP Kearney, AK Cheng. Antiviral activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV-1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. J Infect Dis. 2010;201:814-822.
  3. SA Yukl, AK Shergill, K McQuaid, S Gianella, H Lampiris, CB Hare, M Pandori, E Sinclair, HF Gunthard, M Fischer, JK Wong, DV Havlir. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS. 2010;24:2451-2460.
  4. PW Hunt, SG Deeks, DR Bangsberg, A Moss, E Sinclair, T Liegler, M Bates, G Tsao, H Lampiris, R Hoh, and JN Martin. The independent effect of drug resistance on T cell activation in HIV infection. AIDS. 2006; 20:691-699.
  5. PW Hunt, JN Martin, E Sinclair, B Bredt, E Hagos, H Lampiris, SG Deeks. T Cell Activation is Associated with Lower CD4+ gains in HIV-Infected Patients with Sustained Viral Suppression on Antiretroviral Therapy. J Infect Dis. 2003;187:1534-1543.
  6. DL Stevens, D. Herr, H. Lampiris, JL Hunt, DH Batts, B Hafkin and the Linezolid MRSA Study Group. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2002;34: 1481-1490.
  7. RT Schooley, P Ruane, RA Myers, H Lampiris, D Berger, I McGowan, S Chen, MD Miller, E Isaacson, J Elder, A McCullough, A Cheng and the Study 902 Team. Tenofovir DF in highly antiretroviral-experienced patients: results from a 48 week, randomized, double blind study. AIDS. 2002;16:1257-1263.
  8. CB Hare, MP Vu, C Grunfeld, H Lampiris. Simvastatin-nelfinavir interaction leading to rhabdomyolysis and death. Clin Infect Dis. 2002; 35:e111-112.
  9. HW Lampiris and DS Maddix. “Clinical Use of Antimicrobial Agents” in Basic and Clinical Pharmacology, 7th Edition, 8th Edition, 9th Edition, 10th Edition. 2006, 2004, 2001, 1997. BG Katzung, editor, McGraw-Hill, New York.